Showing results (691-700 of 1,007) with videos related to

Sort By:
Pageof 101
Frontiers in Transplantation|July 12, 2024
Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA studyWolfgang Arns, Aurélie Philippe, Vanessa Ditt, et al.
Neurology|May 12, 2017
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson diseaseFabrizio Stocchi, Olivier Rascol, Robert A Hauser, et al.
Analytical Chemistry|December 23, 2017
Liquid Chromatography-High Resolution Mass Spectrometry Analysis of Platelet Frataxin as a Protein Biomarker for the Rare Disease Friedreich's AtaxiaLili Guo, Qingqing Wang, Liwei Weng, et al.
Science (New York, N.Y.)|September 15, 1995
Interhemispheric correlation of late pleistocene glacial eventsT V Lowell, C J Heusser, B G Andersen, et al.
Aquatic Toxicology (Amsterdam, Netherlands)|September 27, 2012
Enzymatic GST levels and overall health of mullets from contaminated Brazilian LagoonsF F Bastos, R A Hauser-Davis, S A L Tobar, et al.
Frontiers in Transplantation|July 12, 2024
Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudyAurélie Philippe, Wolfgang Arns, Vanessa Ditt, et al.
Organic Letters|November 15, 2008
First total synthesis of (+/-)-3-hydroxy-11-norcytisine: structure confirmation and biological characterizationDaniel Yohannes, Camilla P Hansen, Srinivasa Rao Akireddy, et al.
Neurology|February 27, 2001
Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort studyT S Walczak, I E Leppik, M D'Amelio, et al.
Movement Disorders Clinical Practice|April 8, 2020
Practical Evaluation and Management of Insomnia in Parkinson's Disease: A ReviewDouglas M Wallace, William K Wohlgemuth, Lynn Marie Trotti, et al.
The American Journal of Psychiatry|March 22, 2017
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive DyskinesiaRobert A Hauser, Stewart A Factor, Stephen R Marder, et al.
Pageof 101